Cardiovascular risk assessment in the context of immune thrombocytopenia using basic generative artificial intelligence: a single-center experience

Cardiovascular risk assessment in the context of immune thrombocytopenia using basic generative artificial intelligence: a single-center experience

Laura del Estal-Jiménez 1, Carmen Rodríguez-Esteban 2, Raquel Iglesias-Varela 3, Raquel Ocampo-Martínez 4, Manuel Rodríguez-López 2

1 Servicio de Hematología y Hemoterapia, Hospital Universitario Álvaro Cunqueiro, EOXI Vigo, Vigo, España; 2 Servicio de Hematología y Hemoterapia, Hospital Universitario Álvaro Cunqueiro, Vigo, Pontevedra, España; 3 Servicio de Hematología y Hemoterapia, Hospital Universitario Álvaro Cunqueiro, EOXI Vigo, Instituto de Investigacion Sanitaria Galicia-SUR, Vigo, España; 4 Servicio de Hematología y Hemoterapia, Hospital Universitario Álvaro Cunqueiro, Instituto de Investigación Sanitaria Galicia Sur, EOXI Vigo, Vigo, España

Laura del Estal-Jiménez, Carmen Rodríguez-Esteban, Raquel Iglesias-Varela, Raquel Ocampo-Martínez, Manuel Rodríguez-López

La información completa de afiliaciones y autor de correspondencia está disponible en la versión original en PDF.

*Correspondence: Carmen Rodríguez-Esteban. Email: carmen.rodriguez.esteban@sergas.es

Summary

Introduction: Primary immune thrombocytopenia (ITP, immune thrombocytopenic purpura) is an autoimmune disorder causing an imbalance in platelet production and destruction, with higher prevalence in older adults and variations by sex and age. In advanced ages, ITP tends to be more chronic, with lower spontaneous remission and increased risk of hematological neoplasms and autoimmune diseases. Objective: To evaluate cardiovascular risk factors (CVRF) in a cohort of adult patients with ITP as part of their comprehensive care. Material and method: CVRF were assessed in 55 patients with primary immune thrombocytopenia, mean age 65.1 years and similar distribution by sex. Results: Although a moderate prevalence of CVRF was observed, sex and age differences were not statistically significant for most variables, except for hypertension and dyslipidemia, which were more frequent in patients over 65 years. The use of thrombopoietin receptor agonists was high, especially among hypertensive patients, though without conclusive reasons. Older patients with more CVRF often received anticoagulants. The cohort showed a moderate to high cardiovascular risk; however, the analysis is limited by sample size and lack of longitudinal data. Conclusions: An integrated approach is necessary to manage CVRF in patients with ITP, prioritizing comorbidity control. Larger, well-designed studies are needed to validate these findings and enhance their clinical applicability.

Keywords:  Primary immune thrombocytopenia. Cardiovascular risk factors. Thrombopoietin receptor agonists. Antiplatelet therapy. Anticoagulation.

Contents